EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Value of Molecular Genetic Measurable Residual Disease ( MRD ) Monitoring in Pediatric Acute Myeloid Leukemia Expressing KMT2A::MLLT10

Emma Steidel iD, Eser Orhan, Mareike Rasche, Martina Pigazzi, Claudia Tregnago, Lina Marie Hoffmeister, Christiane Walter, Michael Dworzak iD, Nora Mühlegger, Nils von Neuhoff, Franco Locatelli, Dirk Reinhardt und 1 weitere

European Journal of Haematology · 2025-11 · 115 (5) · 493-504

DOI: 10.1111/ejh.70019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 13.08.2025. Verfasst von Emma Steidel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology-Oncology, Pediatrics III, University Hospital of Essen, Essen, Germany. Hauptthemen laut MEDLINE: Myeloid-Lymphoid Leukemia Protein, Leukemia, Myeloid, Acute, Histone-Lysine N-Methyltransferase, DNA-Binding Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wirtschaftsagentur Wien.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Pediatric AML with KMT2A::MLLT10 accounts for 10%–15% of KMT2A ‐rearranged AML and is associated with poor prognosis. Lately, the assessment of measurable residual disease (MRD) by reverse transcription quantitative polymerase chain reaction (RT‐qPCR) has become an important tool for disease management; however, in the pediatric setting, it lacks standardized protocols. Therefore, we investigated the prognostic relevance of MRD monitoring by RT‐qPCR during high‐dose polychemotherapy in pediatric patients with AML expressing KMT2A::MLLT10 .

Methods

Using RNA sequencing, we determined the fusion breakpoints and designed RT‐qPCR assays for MRD monitoring. Bone marrow samples collected from 41 patients, who were treated in the AML‐BFM or AIEOP study, were analyzed for MRD by RT‐qPCR.

Results

MRD positivity after the second treatment course resulted in a significantly worse probability of overall survival (pOS) compared to MRD negative patients (33.3% ± 19.2% vs. 80.6% ± 7.8%, p = 0.032). Moreover, the probability of event‐free survival (pEFS) (16.7% ± 15.2% vs. 76.9% ± 8.3%, p = 0.003) and cumulative incidence of relapse (CIR) (83.3% ± 40.8% vs. 19.2% ± 40.2%, p = 0.001) were significantly worse for patients in complete morphologic remission who remained MRD positive after the second treatment course.

Conclusion

Thus, MRD monitoring enables the identification of a subgroup of pediatric patients with AML carrying KMT2A::MLLT10 in complete morphologic remission with a dismal prognosis despite the current intensive therapy regimen. Trial Registration AML‐BFM study 2004: ClinicalTrials.gov Identifier: NCT00111345; AML‐BFM registry 2012 and AML‐BFM study 2012: EudraCT 2013‐000018‐39; AML‐BFM registry 2017: DRKS number: DRKS00013030

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid-Lymphoid Leukemia ProteinLeukemia, Myeloid, AcuteHistone-Lysine N-MethyltransferaseDNA-Binding ProteinsOncogene Proteins, FusionHumansNeoplasm, ResidualChildFemaleMalePrognosisChild, PreschoolAdolescentInfantGene RearrangementAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorTranscription Factors

Stichwörter der Autor:innen

acute myeloid leukemiachildhood leukemiacomplete remissionmeasurable (minimal) residual diseasereal‐time polymerase chain reactionrisk stratification

Substanzen

Myeloid-Lymphoid Leukemia ProteinHistone-Lysine N-MethyltransferaseKMT2A protein, humanMLLT10 protein, humanDNA-Binding ProteinsOncogene Proteins, FusionBiomarkers, TumorTranscription Factors

Autor:innen und Institutionen

  • Department of Pediatric Hematology-Oncology, Pediatrics III, University Hospital of Essen, Essen, Germany.
  • Pediatric Research Network, Essen, Germany.
  • Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Women's and Children's Health, University of Padua, Padua, Italy.
  • Department of Pediatrics, St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
  • St Anna Children's Cancer Research Institute, Vienna, Austria.
  • Department of Pediatric Hematology Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, University of Pavia, Rome, Italy.

ORCID-Profile: Emma Steidel, Michael Dworzak

Förderung

  • Wirtschaftsagentur Wien

Zitieren

APA

Steidel, E., Orhan, E., Rasche, M., Pigazzi, M., Tregnago, C., Hoffmeister, L. M., Walter, C., Dworzak, M., Mühlegger, N., von Neuhoff, N., Locatelli, F., Reinhardt, D., & Schneider, M. (2025). Prognostic Value of Molecular Genetic Measurable Residual Disease ( MRD ) Monitoring in Pediatric Acute Myeloid Leukemia Expressing KMT2A::MLLT10. European Journal of Haematology, 115(5), 493-504. https://doi.org/10.1111/ejh.70019

Vancouver

Steidel E, Orhan E, Rasche M, Pigazzi M, Tregnago C, Hoffmeister LM, et al. Prognostic Value of Molecular Genetic Measurable Residual Disease ( MRD ) Monitoring in Pediatric Acute Myeloid Leukemia Expressing KMT2A::MLLT10. European Journal of Haematology. 2025;115(5):493-504. doi:10.1111/ejh.70019

BibTeX
@article{Steidel2025,
  author = {Steidel, Emma and Orhan, Eser and Rasche, Mareike and Pigazzi, Martina and Tregnago, Claudia and Hoffmeister, Lina Marie and Walter, Christiane and Dworzak, Michael and Mühlegger, Nora and von Neuhoff, Nils and Locatelli, Franco and Reinhardt, Dirk and Schneider, Markus},
  title = {Prognostic Value of Molecular Genetic Measurable Residual Disease ( MRD ) Monitoring in Pediatric Acute Myeloid Leukemia Expressing KMT2A::MLLT10},
  journal = {European Journal of Haematology},
  year = {2025},
  volume = {115},
  number = {5},
  pages = {493--504},
  doi = {10.1111/ejh.70019}
}
Kostenlos starten →